Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 13/20 | 0.78 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.78 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.78 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.59 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11566735 | 0.93 | OPRM1 (0.69) | OPRM1OPRD1OPRK1CACNA1C | |
| SCHEMBL11568645 | 0.92 | OPRM1 (0.68) | OPRM1OPRD1OPRK1 | |
| SCHEMBL3303683 | 0.92 | OPRM1 (0.80) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| SCHEMBL11566020 | 0.91 | OPRM1 (0.66) | OPRM1OPRD1OPRK1 | |
| SCHEMBL11569033 | 0.91 | OPRM1 (0.78) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| SCHEMBL14530925 | 0.90 | OPRM1 (0.77) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| Carfentanil SCHEMBL116222 | 0.88 | OPRM1 (1.00) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| SCHEMBL11564667 | 0.88 | OPRM1 (0.64) | OPRM1OPRD1OPRK1 | |
| [11C]-Carfentanil SCHEMBL29374424 | 0.88 | OPRM1 (1.00) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| Carfentanil SCHEMBL4256090 | 0.87 | OPRM1 (0.98) | OPRM1OPRD1OPRK1CACNA1COPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3998834-A | ANALGESICS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-12-21 | — | — | US | claimed |
| US-20200352917-A1 | MEDICATED SPRAY FOR TREATMENT OF SUBSTANCE ABUSE, OVERDOSE, ADDICTION AND IMPULSE CONTROL DISORDERS | GOOBERMAN LANCE L (US) | 2020-11-12 | — | — | US | disclosed |
| US-20130030184-A1 | ISOTOPICALLY LABELED CHEMICALLY STABLE REAGENTS AND PROCESS FOR THE SYNTHESIS THEREOF | PERKINELMER HEALTH SCIENCES, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130030184-A1 | ISOTOPICALLY LABELED CHEMICALLY STABLE REAGENTS AND PROCESS FOR THE SYNTHESIS THEREOF | PERKINELMER HEALTH SCIENCES, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8058464-B2 | Isotopically labeled chemically stable reagents and process for the synthesis thereof | PERKINELMER HEALTH SCIENCES, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-5420280-A | Piperidin-4-spiro-oxiranes | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1995-05-30 | — | — | US | disclosed |
| US-4179569-A | ANALGESIC INTERMEDIATES | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-12-18 | — | — | US | disclosed |
| US-3998834-A | ANALGESICS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030184-A1 | ISOTOPICALLY LABELED CHEMICALLY STABLE REAGENTS AND PROCESS FOR THE SYNTHESIS THEREOF | ALKBH2, ALKBH3, ALKBH1 | OPRM1 716/4885OPRD1 1225/4885OPRK1 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.